{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"6-month rates of myocardial infarction and stroke will be calculated.","groups":[{"description":"apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months\n\nApixaban: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months","id":"OG000","title":"Apixaban"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months","title":"Frequency of Atherothrombotic Events","type":"SECONDARY","unitOfMeasure":"Participants"}